vu6008667

VU6008667 is a selective **negative allosteric modulator** (NAM) of the **muscarinic acetylcholine receptor subtype 5 (M5 mAChR)**. It is a **small molecule** with **high CNS penetration** and was developed as a short half-life research tool for addiction and drug dependence studies. VU6008667 inhibits M5 receptor-mediated signaling in the brain, interfering with reinforcement from opioid self-administration, reducing relapse, and potentially lowering risk for the development of opioid use disorder. It has demonstrated efficacy in preclinical animal models, attenuating oxycodone self-administration and cue-induced reinstatement, without significantly impairing motor coordination or learning. The compound was developed by Vanderbilt University, primarily for investigation in substance use disorders, especially opioid use disorder[1][2][3][4][7][9].

Other names

VU6008667VU-6008667VU 6008667(Rac)-VU 6008667